Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
BMY
Bristol-Myers Squibb Company
Opdivo is a monoclonal antibody immuno-oncology therapy, a core direct product in BMY's Growth Portfolio.
|
$100.25B |
$49.25
+0.41%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Regeneron’s core business centers on monoclonal antibody therapeutics (e.g., Dupixent, Libtayo).
|
$83.16B |
$784.81
-0.32%
|
|
IDXX
IDEXX Laboratories, Inc.
IDEXX launched the IDEXX Cancer Dx panel, a cancer diagnostic test aligned with companion diagnostics for oncology.
|
$60.48B |
$756.04
-1.39%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
Alnylam's core product modality is RNA interference (RNAi) therapeutics, including approved products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
|
$58.35B |
$445.07
+3.55%
|
|
ZTS
Zoetis Inc.
Zoetis markets vaccines for companion animals and livestock, a major revenue and product category.
|
$56.59B |
$127.69
-0.16%
|
|
BDX
Becton, Dickinson and Company
BD develops drug delivery platforms and related biologic‑delivery solutions for therapeutics including GLP‑1s and wearables.
|
$55.58B |
$193.94
-0.79%
|
|
ARGX
argenx SE
argenx's core offerings are monoclonal antibody therapeutics, including VYVGART.
|
$54.87B |
$917.91
-0.00%
|
|
CAH
Cardinal Health, Inc.
Nuclear medicine radiopharmaceuticals distribution and related imaging agents.
|
$50.90B |
$213.13
-0.28%
|
|
TAK
Takeda Pharmaceutical Company Limited
Takeda is a large-cap pharmaceutical company with a diversified, high-revenue drug portfolio and pipeline.
|
$46.03B |
$14.52
+0.10%
|
|
HLN
Haleon plc
Panadol and other analgesics position Haleon in OTC Pain Relief & Analgesics.
|
$44.57B |
$9.76
-0.61%
|
|
A
Agilent Technologies, Inc.
BIOVECTRA acquisition expands Agilent's contract manufacturing capabilities (CDMO) for advanced modalities.
|
$43.85B |
$154.34
-1.82%
|
|
INSM
Insmed Incorporated
Brensocatib is an oral small molecule therapeutic targeting DPP1, a core part of Insmed's pipeline.
|
$43.23B |
$204.49
-2.17%
|
|
IQV
IQVIA Holdings Inc.
IQVIA operates as outsourced drug development and clinical research services akin to a CRO.
|
$39.41B |
$231.92
|
|
ALC
Alcon Inc.
Alcon markets ophthalmic drugs and prescription eye drops like Tryptyr.
|
$39.16B |
$79.19
-0.59%
|
|
ONC
BeOne Medicines Ltd.
Core oncology-focused biotech; primary business segment is oncology therapeutics.
|
$37.52B |
$340.81
+1.68%
|
|
GEHC
GE HealthCare Technologies Inc.
GE HealthCare markets proprietary radiopharmaceuticals (e.g., Flyrcado) and radiopharmaceutical diagnostics.
|
$36.81B |
$80.62
+0.83%
|
|
KVUE
Kenvue Inc.
Kenvue directly manufactures and sells OTC analgesics (e.g., Tylenol).
|
$33.05B |
$17.21
+1.06%
|
|
BIIB
Biogen Inc.
Biogen's LEQEMBI is an Alzheimer's disease therapeutic, a direct product the company manufactures and sells.
|
$26.68B |
$181.93
-0.02%
|
|
BNTX
BioNTech SE
The company is pivoting toward oncology with immunotherapies, making Biotech - Oncology a core product/business focus.
|
$24.62B |
$102.73
+3.03%
|
|
PODD
Insulet Corporation
The insulin delivery platform functions as a drug delivery platform enabled by a medical device.
|
$23.00B |
$326.89
-0.60%
|
|
LH
Labcorp Holdings Inc.
Labcorp functions as aContract Research Organization offering outsourced drug development and regulatory support services.
|
$22.29B |
$268.36
-0.28%
|
|
JBL
Jabil Inc.
Aseptic filling and dry oral dosage capabilities via Pharmaceutics International (Pii) reflect contract manufacturing services in pharma.
|
$22.24B |
$207.29
+1.62%
|
|
UTHR
United Therapeutics Corporation
UTHR's core PAH/CV therapy portfolio centers on prostacyclin cardiovascular drugs, including Tyvaso, Remodulin, Orenitram, and Ralinepag (where applicable).
|
$22.09B |
$488.57
+0.58%
|
|
GMAB
Genmab A/S
Genmab is a biotechnology company focused on oncology therapeutics, fitting Biotech - Oncology.
|
$21.12B |
$31.93
+1.67%
|
|
INCY
Incyte Corporation
Monoclonal Antibody Therapeutics is a direct product modality for Monjuvi (tafasitamab) and similar antibody-based cancer therapies.
|
$20.63B |
$105.75
+0.19%
|
Showing page 2 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
